Advertisement

Loss of Cdh1 Triggers Premature Senescence in Part via Activation of Both the RB/E2F1 and the CLASPIN/CHK1/P53 Tumor Suppressor Pathways

  • Shavali Shaik
  • Pengda Liu
  • Zhiwei Wang
  • Wenyi Wei
Chapter
Part of the Tumor Dormancy and Cellular Quiescence and Senescence book series (DOQU, volume 2)

Abstract

Senescence is recently characterized as one of the evolutionarily conserved protective mechanisms against tumor development. Several upstream factors including oxidative stress, DNA damage and overexpression of certain oncoproteins have been shown to induce premature senescence. Interestingly, it has been discovered that instead of promoting tumorigenesis, loss of certain tumor suppressors such as TSC2, PTEN and NF1 induce premature senescence under certain conditions, presumably by activating the downstream oncoproteins mTORC1/S6k, Akt and Ras, respectively. Interestingly, it has been observed by multiple groups that acute loss of Cdh1 also leads to premature senescence in several cellular settings including mouse embryonic fibroblasts and human primary fibroblasts. This is in part due to the fact that Cdh1 loss leads to stabilization of Ets2, which increases p16 expression and causes premature senescence. Moreover, recent studies from our laboratory further suggested that loss of Cdh1 results in the activation of both the Claspin/Chk1/p53 and the Rb/E2F1 pathways, which ultimately leads to premature senescence in primary human fibroblasts but not in transformed cells with defective p53/Rb pathways. Therefore, our studies support the idea that onset of premature senescence serves as a protection mechanism against sporadic tumorigenesis. It also indicates that loss of Cdh1 tumor suppressor is a relatively late event, which only benefits tumorigenesis for late stage tumors with defective Rb and p53 tumor suppressor pathways. More importantly, our results also indicate that Cdh1 could be an anti-cancer target in certain settings, as complete inactivation of Cdh1 in early stage tumors with wild-type p53 and Rb pathways will lead to induction of premature senescence, thereby aiding tumor regression.

Keywords

Anaphase-promoting complex (APC/C) Cyclin-dependent protein kinases (Cdks) DNA binding activity of p53 DNA damage Expression of PTEN Mouse embryonic fibroblasts (MEFs) Regulation of Cdh1 Skp1-Cullin1-F-box complex (SCF) Ubiquitin proteasome system (UPS) 

Notes

Acknowledgements

This work was supported in part from the grants (GM089763 and GM094777) from National Institutes of Health to Wenyi Wei. Shavali Shaik, Pengda Liu and Zhiwei Wang were supported by the institutional NRSA T-32 training grant.

References

  1. Bloom J, Cross FR (2007) Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol 8:149–160PubMedCrossRefGoogle Scholar
  2. Campisi J (1996) Replicative senescence: an old lives’ tale? Cell 84:497–500PubMedCrossRefGoogle Scholar
  3. Campisi J, d’Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8:729–740PubMedCrossRefGoogle Scholar
  4. Cao L, Li W, Kim S, Brodie SG, Deng CX (2003) Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev 17:201–213PubMedCrossRefGoogle Scholar
  5. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38:1043–1048PubMedCrossRefGoogle Scholar
  6. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, Cichowski K (2006) A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10:459–472PubMedCrossRefGoogle Scholar
  7. Dial JM, Petrotchenko EV, Borchers CH (2007) Inhibition of APCCdh1 activity by Cdh1/Acm1/Bmh1 ternary complex formation. J Biol Chem 282:5237–5248PubMedCrossRefGoogle Scholar
  8. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92:9363–9367PubMedCrossRefGoogle Scholar
  9. Doree M, Galas S (1994) The cyclin-dependent protein kinases and the control of cell division. FASEB J 8:1114–1121PubMedGoogle Scholar
  10. Frescas D, Pagano M (2008) Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8:438–449PubMedCrossRefGoogle Scholar
  11. Gao D, Inuzuka H, Korenjak M, Tseng A, Wu T, Wan L, Kirschner M, Dyson N, Wei W (2009a) Cdh1 regulates cell cycle through modulating the claspin/Chk1 and the Rb/E2F1 pathways. Mol Biol Cell 20:3305–3316PubMedCrossRefGoogle Scholar
  12. Gao D, Inuzuka H, Tseng A, Chin RY, Toker A, Wei W (2009b) Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol 11:397–408PubMedCrossRefGoogle Scholar
  13. Garcia-Higuera I, Manchado E, Dubus P, Canamero M, Mendez J, Moreno S, Malumbres M (2008) Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol 10:802–811PubMedCrossRefGoogle Scholar
  14. Hsu JY, Reimann JD, Sorensen CS, Lukas J, Jackson PK (2002) E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat Cell Biol 4:358–366PubMedCrossRefGoogle Scholar
  15. Hwang ES, Yoon G, Kang HT (2009) A comparative analysis of the cell biology of senescence and aging. Cell Mol Life Sci 66:2503–2524PubMedCrossRefGoogle Scholar
  16. Kraft C, Vodermaier HC, Maurer-Stroh S, Eisenhaber F, Peters JM (2005) The WD40 propeller domain of Cdh1 functions as a destruction box receptor for APC/C substrates. Mol Cell 18:543–553PubMedCrossRefGoogle Scholar
  17. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS (2010) The essence of senescence. Genes Dev 24:2463–2479PubMedCrossRefGoogle Scholar
  18. Li M, Shin YH, Hou L, Huang X, Wei Z, Klann E, Zhang P (2008) The adaptor protein of the anaphase promoting complex Cdh1 is essential in maintaining replicative lifespan and in learning and memory. Nat Cell Biol 10:1083–1089PubMedCrossRefGoogle Scholar
  19. Listovsky T, Oren YS, Yudkovsky Y, Mahbubani HM, Weiss AM, Lebendiker M, Brandeis M (2004) Mammalian Cdh1/Fzr mediates its own degradation. EMBO J 23:1619–1626PubMedCrossRefGoogle Scholar
  20. Lukas C, Sorensen CS, Kramer E, Santoni-Rugiu E, Lindeneg C, Peters JM, Bartek J, Lukas J (1999) Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 401:815–818PubMedCrossRefGoogle Scholar
  21. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G (2007) The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 21:43–48PubMedCrossRefGoogle Scholar
  22. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G, Hara E (2001) Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409:1067–1070PubMedCrossRefGoogle Scholar
  23. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593–602PubMedCrossRefGoogle Scholar
  24. Shaik S, Liu P, Fukushima H, Wang Z, Wei W (2012) Protein degradation in cell cycle. In: Yixian Zheng (ed) eLS. Wiley, Chichester, pp 1–8Google Scholar
  25. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C (2000) The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14:289–300PubMedGoogle Scholar
  26. Sitte N, Merker K, von Zglinicki T, Grune T (2000) Protein oxidation and degradation during proliferative senescence of human MRC-5 fibroblasts. Free Radic Biol Med 28:701–708PubMedCrossRefGoogle Scholar
  27. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, Pandolfi PP (2011) Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 144:187–199PubMedCrossRefGoogle Scholar
  28. Sudo T, Ota Y, Kotani S, Nakao M, Takami Y, Takeda S, Saya H (2001) Activation of Cdh1-dependent APC is required for G1 cell cycle arrest and DNA damage-induced G2 checkpoint in vertebrate cells. EMBO J 20:6499–6508PubMedCrossRefGoogle Scholar
  29. Vodermaier HC (2004) APC/C and SCF: controlling each other and the cell cycle. Curr Biol 14:R787–R796PubMedCrossRefGoogle Scholar
  30. Wan L, Zou W, Gao D, Inuzuka H, Fukushima H, Berg AH, Drapp R, Shaik S, Hu D, Lester C, Eguren M, Malumbres M, Glimcher LH, Wei W (2011) Cdh1 regulates osteoblast function through an APC/C-independent modulation of Smurf1. Mol Cell 44:721–733PubMedCrossRefGoogle Scholar
  31. Wang CX, Fisk BC, Wadehra M, Su H, Braun J (2000) Overexpression of murine fizzy-related (fzr) increases natural killer cell-mediated cell death and suppresses tumor growth. Blood 96:259–263PubMedGoogle Scholar
  32. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin WG Jr (2004) Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428:194–198PubMedCrossRefGoogle Scholar
  33. Young AP, Schlisio S, Minamishima YA, Zhang Q, Li L, Grisanzio C, Signoretti S, Kaelin WG Jr (2008) VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 10:361–369PubMedCrossRefGoogle Scholar
  34. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112:1223–1233PubMedGoogle Scholar
  35. Zhou Y, Ching YP, Chun AC, Jin DY (2003) Nuclear localization of the cell cycle regulator CDH1 and its regulation by phosphorylation. J Biol Chem 278:12530–12536PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Shavali Shaik
    • 1
  • Pengda Liu
    • 1
  • Zhiwei Wang
    • 1
  • Wenyi Wei
    • 1
  1. 1.Department of Pathology, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA

Personalised recommendations